In Vitro Evaluation of Nonnucleoside Reverse Transcriptase Inhibitors UC-781 and TMC120-R147681 as Human Immunodeficiency Virus Microbicides

ABSTRACT The nonnucleoside reverse transcriptase inhibitors UC-781 and TMC120-R147681 (Dapivirine) effectively prevented human immunodeficiency virus (HIV) infection in cocultures of monocyte-derived dendritic cells and T cells, representing primary targets in sexual transmission. Both drugs had a favorable therapeutic index. A 24-h treatment with 1,000 nM UC-781 or 100 nM TMC120-R147681 prevented cell-free HIV infection, whereas 10-fold-higher concentrations blocked cell-associated HIV.

[1]  E. De Clercq,et al.  Long-term exposure of HIV type 1-infected cell cultures to combinations of the novel quinoxaline GW420867X with lamivudine, abacavir, and a variety of nonnucleoside reverse transcriptase inhibitors. , 2000, AIDS research and human retroviruses.

[2]  M. Hollingshead,et al.  Efficacy, pharmacokinetics, and in vivo antiviral activity of UC781, a highly potent, orally bioavailable nonnucleoside reverse transcriptase inhibitor of HIV type 1. , 1997, AIDS research and human retroviruses.

[3]  M. Wainberg,et al.  Chemical Barriers to Human Immunodeficiency Virus Type 1 ( HIV-1 ) Infection : Retrovirucidal Activity of UC 781 , a Thiocarboxanilide Nonnucleoside Inhibitor of HIV-1 Reverse Transcriptase , 1996 .

[4]  F. Belardelli,et al.  Inhibition of vaginal transmission of HIV-1 in hu-SCID mice by the non-nucleoside reverse transcriptase inhibitor TMC120 in a gel formulation , 2003, AIDS.

[5]  D. Taylor-Robinson,et al.  Safety study of nonoxynol-9 as a vaginal microbicide: evidence of adverse effects. , 1998, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[6]  L. van Damme,et al.  Preclinical studies on thiocarboxanilide UC‐781 as a virucidal agent , 1998, AIDS.

[7]  P. Vernazza,et al.  Sexual transmission of HIV: infectiousness and prevention. , 1999, AIDS.

[8]  G. Vanham,et al.  Activity of reverse transcriptase inhibitors in monocyte-derived dendritic cells: a possible in vitro model for postexposure prophylaxis of sexual HIV transmission. , 2002, AIDS research and human retroviruses.

[9]  R. Moseley,et al.  Observations from the CDC. The urgent need for new HIV/STD prevention options for women. , 1998, Journal of women's health.

[10]  R. Short.  Contraceptives of the Future in the Light of HIV Infection , 1994, The Australian & New Zealand journal of obstetrics & gynaecology.

[11]  C. Morrison,et al.  The effectiveness of barrier methods of contraception in preventing the spread of HIV. , 1995, AIDS.

[12]  A I Spira,et al.  Cellular targets of infection and route of viral dissemination after an intravaginal inoculation of simian immunodeficiency virus into rhesus macaques , 1996, The Journal of experimental medicine.

[13]  Hui Zhang,et al.  Human immunodeficiency virus type 1 in the semen of men receiving highly active antiretroviral therapy. , 1998, The New England journal of medicine.

[14]  R. Pauwels,et al.  Evolution of anti-HIV drug candidates. Part 2: Diaryltriazine (DATA) analogues. , 2001, Bioorganic & medicinal chemistry letters.

[15]  R. Pauwels,et al.  Evolution of anti-HIV drug candidates. Part 3: Diarylpyrimidine (DAPY) analogues. , 2001, Bioorganic & medicinal chemistry letters.

[16]  T. Wright,et al.  Correlation of human immunodeficiency virus type 1 RNA levels in blood and the female genital tract. , 1999, The Journal of infectious diseases.

[17]  M. Wainberg,et al.  Attenuated infectivity of HIV type 1 from epithelial cells pretreated with a tight-binding nonnucleoside reverse transcriptase inhibitor. , 2002, AIDS research and human retroviruses.

[18]  Z. Stein,et al.  HIV prevention: the need for methods women can use. , 1990, American journal of public health.

[19]  E. De Clercq,et al.  Kinetics of inhibition of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase by the novel HIV-1-specific nucleoside analogue [2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]-3'-spiro-5 "- (4"-amino-1",2"-oxathiole-2",2"-dioxide)thymine (TSAO-T). , 1992, The Journal of biological chemistry.

[20]  J. Turpin.  Considerations and development of topical microbicides to inhibit the sexual transmission of HIV , 2002, Expert opinion on investigational drugs.

[21]  H. Sheppard,et al.  PCR-Based Assay To Quantify Human Immunodeficiency Virus Type 1 DNA in Peripheral Blood Mononuclear Cells , 2000, Journal of Clinical Microbiology.

[22]  G. Milman,et al.  Mechanisms of HIV/SIV mucosal transmission. , 1994, AIDS research and human retroviruses.

[23]  L. Heise,et al.  Challenges for the development of female-controlled vaginal microbicides. , 1994, AIDS.